Now I have thoroughly read the paper and verified all claims. Let me produce the final consolidated review.

## Summary

MUSE addresses multimodal patient representation learning under *both* missing modalities and missing labels—a practically important but underexplored setting. It constructs a bipartite patient-modality graph (flexible to any missing-modality pattern) and applies a mutual-consistent contrastive loss: an unsupervised term (InfoNCE over edge-dropout-augmented graphs) encourages modality-agnostic representations, while a supervised term pulls same-label patients together. Evaluated on MIMIC-IV, eICU, and ADNI, MUSE consistently outperforms imputation, direct-prediction, and graph-based baselines by ~2–4% absolute AUC-ROC.

## Strengths

- **Well-motivated, realistic problem formulation.** The paper clearly distinguishes between (a) complete data, (b) missing modalities only, and (c) both missing modalities and missing labels—a distinction prior work largely ignores. This reframing is an important step toward clinically applicable multimodal learning.

- **Clean method with complementary objectives that ablation validates.** The unsupervised contrastive loss encourages modality-agnostic features; the supervised loss encourages label-decisive features. The ablation (Table 3) confirms that removing either term (A3, A4) degrades performance and that both contribute non-redundantly, supporting the design rationale.

- **Consistent, statistically significant improvements across three diverse datasets.** MUSE (labeled-only training) outperforms all baselines on MIMIC-IV, eICU, and ADNI (Tables 1–2) with ~2–4% absolute gains and p < 0.05 significance. The result is robust across datasets of different sizes and tasks.

- **Empirical evidence of modality-agnostic representations.** Figure 4 directly measures cosine similarity between a patient's representation from full modalities vs. a masked version. MUSE achieves the highest similarity among all methods, quantitatively supporting the claim that its representations are less dependent on specific modalities.

## Weaknesses

### Fatal
None.

### Major

- **The missing-labels claim (MUSE+) is insufficiently validated.** MUSE+ extends training to unlabeled patients via the unsupervised contrastive loss and outperforms baselines that *cannot use unlabeled data at all*. The ~2% additional gain over MUSE could simply reflect having more training data—any semi-supervised method would likely show some improvement. The paper does not compare against semi-supervised adaptations of strong baselines (e.g., GRAPE + pseudo-labeling or consistency regularization), so we cannot determine whether MUSE+'s specific design, rather than the mere availability of extra data, drives the improvement. Since "missing labels" appears in the title, abstract, and contribution statement, this gap weakens a central claim.

- **The benefit of the bipartite graph architecture over simpler fusion is not isolated.** The ablation study removes contrastive objectives and edge dropout but never replaces the graph structure itself with a simpler alternative (e.g., mean-pooling or concatenation of available modality embeddings followed by the same contrastive losses). Without this control, it is unclear whether the bipartite graph itself contributes meaningfully, or whether the contrastive objectives alone (applied on top of any reasonable fusion) would suffice.

### Minor

- **The modality-collapse analysis is correlational, not causal.** Figure 4 shows that MUSE yields higher cosine similarity across modality subsets, which the paper interprets as evidence of reduced modality collapse. However, no experiment *directly* tests reliance on specific modalities (e.g., removing one modality at test time and measuring the performance drop). The connection between cosine similarity and downstream robustness is plausible but not rigorously demonstrated.

- **Natural missing-modality patterns in the datasets are not reported.** The main results (Tables 1–2) use the real-world missing patterns, but the paper never describes them (e.g., what fraction of patients lack each modality). This makes it hard to assess whether the evaluation setting is realistic or how the problem's difficulty compares across datasets.

- **MUSE+ vs. MUSE significance is not reported.** The paper reports t-tests comparing MUSE against baselines but does not test whether MUSE+ significantly outperforms MUSE. Given the modest additional gain (~2%), this comparison would clarify whether the improvement is meaningful.

- **Cosine similarity results (Figure 4) lack reported confidence intervals or error bars**, weakening the quantitative support for the modality-agnostic claim.

### Trivial
None.

## Nice-to-Haves

- **Semi-supervised baselines:** Compare MUSE+ against, e.g., GRAPE with self-training/pseudo-labels on unlabeled patients. This would directly validate the missing-labels claim.
- **Ablation without the graph:** Replace the bipartite graph with mean-pooling or concatenation of modality embeddings (keeping the same contrastive losses) to isolate the graph structure's contribution.
- **Modality-removal test:** For each modality, measure the performance drop when removing it at test time, to causally test modality-collapse mitigation.
- **Edge-dropout sensitivity analysis:** Show how patients with only 1–2 modalities are affected by the 15% dropout rate (e.g., fraction of patients left with zero edges in the augmented graph).
- **t-SNE/UMAP visualizations** of patient representations colored by label and by missing-modality pattern.

## Removed Points

*"The figure caption says prediction performance vs. training time. The points in the figure are not labeled in the extracted text (likely a parser issue), so it is hard to interpret."* — This is a parser/formatting artifact; the original figure is properly labeled. Removed per hard rules.

*"The paper does not discuss missing related works"* / *"the broader literature on missing data and semi-supervised learning is not discussed"* — Per instructions, missing-related-work criticisms are removed since I cannot independently verify which works are missing. Also, the paper does site relevant related work in Section 5.

*Critique regarding "the unsupervised component only requires self-supervision signals... this is trivially true"* — This is a statement of fact, not a weakness. The contribution is that the unsupervised loss *enables* leveraging unlabeled patients, not that it trivially doesn't use labels. Removed.

*Critique that standard deviations exceed 0.02 on ADNI* — The paper honestly flags this with a dagger and explains it (smaller dataset). This is transparent reporting, not a weakness.

*Demand for investigating temperature parameter τ* — This is a standard hyperparameter; not investigating it in the paper is not a weakness.

*Suggestions to extend to multi-label or regression tasks* — Outside the paper's stated scope.

## Novel Insights

None beyond the paper's own contributions. The two insights the paper articulates (flexible bipartite graph for missing-modality patterns, and a contrastive objective that simultaneously encourages modality-agnostic and label-decisive features) are the core novel ideas, and the reviews add no additional observations beyond confirming or questioning them.

## Suggestions

1. **Strengthen the missing-labels claim.** Add semi-supervised baselines (GRAPE + pseudo-labeling, consistency regularization) so that MUSE+ is compared against methods that also use unlabeled data. If the gap persists, the claim is validated; if not, reframe the contribution accordingly.
2. **Isolate the graph contribution.** Add an ablation that replaces the bipartite graph with a simple fusion (e.g., mean-pooling of available modality embeddings) while keeping the same contrastive losses.
3. **Add a direct modality-removal experiment.** Report performance when each modality is dropped at test time, to causally demonstrate modality-collapse mitigation.
4. **Report natural missing-modality statistics** for each dataset to contextualize the problem setting.
5. **Report statistical significance of MUSE+ vs. MUSE** to clarify whether the unlabeled-data gains are meaningful.

## Score and Decision

**Originality:** 7/10 — The problem framing (joint missing modalities and labels) is novel, though each subproblem individually is well-studied. The bipartite graph + contrastive design is clean but builds on existing ideas (GRAPE, contrastive learning).

**Importance of research question:** 8/10 — The question is practically important for clinical ML, where both missing modalities and labels are the norm.

**Claims support:** 6/10 — The missing-modalities claim is well-supported; the missing-labels claim is under-evidenced due to the lack of semi-supervised baselines and the graph-structure ablation.

**Soundness of experiments:** 7/10 — Generally sound but incomplete in the two areas noted as major weaknesses. The evaluation covers diverse datasets, tasks, and includes statistical significance testing.

**Clarity of writing:** 8/10 — Well-structured, with clear motivation and method description. The figures effectively convey the framework.

**Value to the research community:** 7/10 — The method and code release will be useful for practitioners working with clinical multimodal data, and the problem framing may inspire future work on joint missing-data handling.

MY FINAL SCORE: <pineapple>7.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>